Improving Patient Outcomes With Inguinal Hernioplasty - a Randomized Controlled Trial of Local Anaesthesia Versus Local Anaesthesia and Conscious Sedation
| Registry | NCT02444260 |
|---|---|
| Status | Unknown |
| Phase | Phase 3 |
| Study type | Interventional; randomized, parallel, masking: triple, treatment |
| Enrollment | 180 (Estimated) |
| Sponsor | The University of The West Indies (Other) |
| Conditions | Inguinal Hernia, Anesthesia, Local, Conscious Sedation |
| Interventions | Midazolam, Intravenous Normal Saline, Bupivocaine, Lignocaine HCl (Drug) |
| Dates | start 2013-12-01, primary completion 2015-12-01 (estimated), completion 2016-12-01 (estimated), first posted 2015-05-14, last updated 2015-05-14 |
| Locations | 1 site in Jamaica |
Related Papers Related Patents Related Grants Related Experts
All trials for Inguinal Hernia All trials for Anesthesia, Local All trials of Midazolam All trials of Intravenous Normal Saline
The aim of this RCT is to compare patient outcomes of inguinal hernioplasty under Local Anaesthesia alone versus Local Anaesthesia and Conscious Sedation
Specific study objectives are to determine the effect of conscious sedation on:
(i) patient satisfaction (ii) postoperative pain (iii) time to discharge (iv) intraoperative complications (v) postoperative functional status (vi) short-term postoperative complications (vii) long-term postoperative complications
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Intravenous Normal Saline | Sham comparator | Drug: Intravenous Normal Saline; Drug: Bupivocaine; Drug: Lignocaine HCl | Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i |
| Midazolam | Active comparator | Drug: Midazolam; Drug: Bupivocaine; Drug: Lignocaine HCl | Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. |
Sex: All, ages: 18 Years to 75 Years
Inclusion Criteria: * Reducible inguinal hernia Exclusion Criteria: * Renal, hepatic, respiratory, cardiovascular, neurologic or psychiatric disease * Body mass index < 18.5 kg/m2 or > 30 kg/m2 * Recurrent inguinal hernias * Bilateral inguinal hernias * Large inguinoscrotal hernias * Incarcerated hernia * Allergies to local anaesthetic and sedative agents * Pregnancy * Lactation * Chronic pain syndromes * Anxiety disorders * Marijuana use * Long term use of opioid or sedative agents
| Facility | City | Country | Status |
|---|---|---|---|
| University of the West Indies, mona | Kingston, Please Select | Jamaica | Recruiting |